These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 7688656

  • 1. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
    Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS.
    Cancer; 1993 Sep 01; 72(5):1685-91. PubMed ID: 7688656
    [Abstract] [Full Text] [Related]

  • 2. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG.
    Urology; 1999 May 01; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [Abstract] [Full Text] [Related]

  • 3. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
    Sugiono M, Winkler MH, Okeke AA, Benney M, Gillatt DA.
    Prostate Cancer Prostatic Dis; 2005 May 01; 8(1):91-4. PubMed ID: 15711607
    [Abstract] [Full Text] [Related]

  • 4. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB.
    J Urol; 2001 May 01; 165(5):1585-9. PubMed ID: 11342922
    [Abstract] [Full Text] [Related]

  • 5. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
    Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K.
    Urology; 1995 May 01; 45(5):839-44; discussion 844-5. PubMed ID: 7538246
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S, Lawrentschuk N, Grills RJ, Neerhut G.
    J Urol; 2005 Jul 01; 174(1):140-2. PubMed ID: 15947599
    [Abstract] [Full Text] [Related]

  • 7. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB, Mottet N.
    BJU Int; 2012 Aug 01; 110(4):499-504. PubMed ID: 22093775
    [Abstract] [Full Text] [Related]

  • 8. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen.
    Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD.
    Cancer; 1993 May 01; 71(9):2782-90. PubMed ID: 7682149
    [Abstract] [Full Text] [Related]

  • 9. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW, Uitterlinden P, de Jong FH.
    Cancer Res; 1988 Nov 01; 48(21):6063-8. PubMed ID: 2844399
    [Abstract] [Full Text] [Related]

  • 10. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
    Koh Y, Kawashima A, Ujike T, Nagahara A, Fujita K, Kiuchi H, Imamura R, Miyagawa Y, Nonomura N, Uemura M.
    Anticancer Drugs; 2020 Nov 01; 31(10):1099-1102. PubMed ID: 32804697
    [Abstract] [Full Text] [Related]

  • 11. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H, Senge T.
    J Urol; 1990 Oct 01; 144(4):934-41. PubMed ID: 2144596
    [Abstract] [Full Text] [Related]

  • 12. Estramustine phosphate for preventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy.
    Shimizu TS, Shibata Y, Jinbo H, Satoh J, Yamanaka H.
    Eur Urol; 1995 Oct 01; 27(3):192-5. PubMed ID: 7541359
    [Abstract] [Full Text] [Related]

  • 13. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H, Varenhorst E, Svensson M, Kågedal B, Nordenskjöld B.
    Acta Oncol; 1988 Oct 01; 27(4):361-4. PubMed ID: 2974290
    [Abstract] [Full Text] [Related]

  • 14. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.
    Krakowsky Y, Morgentaler A.
    Eur Urol Focus; 2019 Jan 01; 5(1):81-89. PubMed ID: 28753828
    [Abstract] [Full Text] [Related]

  • 15. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM.
    J Urol; 1988 Dec 01; 140(6):1460-5. PubMed ID: 2973529
    [Abstract] [Full Text] [Related]

  • 16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T, Nishizawa K, Mitsumori K.
    Scand J Urol Nephrol; 2006 Dec 01; 40(3):198-203. PubMed ID: 16809259
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H, Noguchi K, Kinoshita Y, Hosaka M, Kawasaki C, Miura T, Kondo I, Harada M.
    Hinyokika Kiyo; 2000 Aug 01; 46(8):531-6. PubMed ID: 11019371
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.
    Goldspiel BR, Kohler DR.
    DICP; 1991 Aug 01; 25(7-8):796-804. PubMed ID: 1835221
    [Abstract] [Full Text] [Related]

  • 20. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL.
    J Clin Oncol; 1987 Jun 01; 5(6):912-7. PubMed ID: 2953870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.